Quick Facts on Uses

• Partial-Onset Seizures: Approved for use alone or alongside other medications in patients with epilepsy who are 4 years of age and older.
• Primary Generalized Tonic-Clonic Seizures (PGTC): Approved for use alongside other medications in patients with epilepsy who are 12 years of age and older.

---

What Fycompa Treats: Main Uses and Benefits

Fycompa (perampanel) is an available therapeutic option used to help manage specific types of seizures in patients with epilepsy. The drug is intended to address symptoms associated with seizures by reducing their frequency.

Fycompa is approved for the management of partial-onset seizures in individuals aged 4 years and older. For this indication, the medication may be administered as monotherapy (alone) or as adjunctive therapy (with other medicines).

Additionally, this medicine is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. For this use, it is always utilized alongside other antiseizure medications. Clinical trials indicate that, for some patients, treatment with perampanel may contribute to a reduction in seizure occurrence.

Fycompa (perampanel) eligibility is defined by regulatory bodies based on age, organ function, and psychiatric history.

Eligibility Scope

Eligibility Status	Population Group	Regulatory Basis
Approved Use	Partial-Onset Seizures: Patients 4 years and older	FDA/EMA
Approved Use	PGTC Seizures: Patients 12 years and older	FDA/EMA
Not Recommended	Patients with severe hepatic impairment	FDA/EMA Labeling
Not Recommended	Patients with severe renal impairment or on hemodialysis	FDA/EMA Labeling
Contraindication	Patients with known hypersensitivity to perampanel	General Monograph

Age and Condition Restrictions

Use of the medicine is not established for children younger than 4 years of age with partial-onset seizures, or for children younger than 12 years of age with primary generalized tonic-clonic (PGTC) seizures.

Patients with a prior history of serious psychiatric and behavioral reactions must be closely monitored due to the potential for severe reactions, which may necessitate discontinuation of the medicine.

For older adults, no dose adjustment is officially required based on age alone. The official labeling notes that the medicine should be used with caution in these patients.

Women who are pregnant or breastfeeding should consult their healthcare provider, as it is not known if the medicine will harm an unborn baby or pass into breast milk.

Interactions with other medicines and products

The official regulatory profile for Fycompa (perampanel) identifies clinically significant interactions based on pharmacokinetic and pharmacodynamic mechanisms, strictly documented in official government sources.

Pharmacokinetic and Pharmacodynamic Interactions

Category	Interacting Substances	Officially Documented Outcome
Enzyme-Inducing Medicines	Carbamazepine, Phenytoin, Oxcarbazepine	Significantly increase the clearance of Perampanel, leading to a substantial reduction in its plasma concentration and exposure.
Hormonal Contraceptives	Levonorgestrel-containing products	Perampanel at the highest labeled dose (12 mg/day) reduces the exposure of levonorgestrel, potentially diminishing contraceptive effectiveness.
CNS Depressants	Alcohol (Ethanol), Other sedating medicines	Co-use results in additive central nervous system (CNS) depression and potentiation of psychiatric effects.

Restrictions and Population Notes

Official labels strictly require the avoidance of alcohol due to the risk of exacerbated CNS effects. Use is not recommended in patients with severe hepatic impairment or severe renal impairment/hemodialysis due to the high risk of reduced Perampanel clearance, which could result in increased and prolonged drug exposure. The regulatory documents confirm that no clinically relevant transporter-mediated interactions are documented, and there are no known interactions with food.

Fycompa (perampanel) functions as a selective non-competitive antagonist of the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor). The AMPA receptor is a major ionotropic glutamate receptor found post-synaptically in the central nervous system, mediating fast excitatory synaptic transmission.

Fycompa exerts its action by binding to an allosteric site on the AMPA receptor complex. This interaction stabilizes the receptor in a closed conformation, which prevents glutamate from fully opening the ion channel pore. This antagonistic action effectively reduces neuronal excitability mediated by glutamate, the brain's primary excitatory neurotransmitter.

By limiting the influx of positive ions (primarily Na^+ and Ca^2+) into the post-synaptic neuron, Fycompa decreases the frequency of action potential generation and the overall level of electrical activity. The system-level physiological consequence of this targeted inhibition is a stabilization of electrical activity across hyperexcitable neural circuits, diminishing the propagation of excitatory signals within neural networks.

How Fycompa is Used: Official Administration Guidelines

The usage of Fycompa (perampanel) is governed by a structured, oral dosing protocol. The medicine is available as film-coated tablets and an oral suspension.

---

Administration and Timing

Fycompa is intended for oral administration and is taken once daily. The recommendation is to take the dose at bedtime. It may be taken with or without food.

Instruction	Detail
Tablet Handling	Tablets must be swallowed whole; they are not to be crushed, chewed, or split.
Suspension Preparation	The oral suspension must be shaken well before use and accurately measured using the provided dosing device.

---

Dosing and Titration Protocol

The medication follows a gradual titration schedule to reach a maintenance range. The dosing rules apply to adults and adolescents aged 12 years and older, with pediatric dosing generally following a similar pattern.

Regimen Element	Standard Instructions (Absence of Inducers)
Initial Dose	2 mg once daily.
Titration Rate	Increase by 2 mg increments.
Titration Frequency	No more frequently than at 7-day (weekly) intervals.
Maximum Dose	12 mg once daily.

---

Special Procedural Conditions

Dose adjustments are mandatory under certain circumstances. The dosing protocol must be modified when Fycompa is used with moderate or strong enzyme-inducing antiepileptic drugs (AEDs), requiring a higher initial dose (4 mg). Furthermore, the dose is restricted and the titration rate is slowed (e.g., every two weeks) for patients with mild to moderate hepatic impairment. The treatment course requires gradual discontinuation (tapering) to reduce the potential for increased seizure frequency.

Research Evidence / Overview of Studies for Fycompa (Perampanel)

---

Research Evidence for Partial-Onset Seizures (POS) – Adjunctive Therapy

Research focused on this indication primarily through multiple short-term, randomized, double-blind, placebo-controlled Phase III trials. These studies examined adults and adolescents (aged 12 years and older) with partial-onset seizures whose condition was characterized by fluctuating or episodic manifestations despite existing treatment. Researchers monitored the median percent change in seizure frequency over a 28-day period and measured the proportion of patients who achieved at least a 50% reduction in seizure frequency.

Studies reported measurements of a difference in the median percentage change in seizure frequency between the perampanel and placebo groups. The results apply only to the populations studied (refractory epilepsy), and data for certain groups remain insufficient, providing limited insight into individuals who may be newly diagnosed or who have non-refractory seizure types.

---

Research Evidence for Primary Generalized Tonic-Clonic Seizures (PGTC) – Adjunctive Therapy

Research examining Fycompa in combination with other AEDs for PGTC seizures is derived from a single, pivotal, short-term, randomized, placebo-controlled trial. This study evaluated patients (aged 12 years and older) who experienced PGTC seizures, a condition characterized by fluctuating or episodic manifestations, while also receiving one or more other anti-epileptic drugs.

The pivotal trial data show patterns related to a difference in the median percent change in PGTC seizure frequency between the perampanel group and the placebo group. The trial also reported a difference in the proportion of patients who met the measured endpoint of seizure freedom during the maintenance phase when comparing the groups. However, the evidence is limited as it relies heavily on one central randomized trial.

---

Research Evidence for Partial-Onset Seizures (POS) – Monotherapy

The evidence base for Fycompa as a sole treatment for partial-onset seizures (monotherapy) was studied for this use under a different regulatory context. The monotherapy evidence base was assessed through the extrapolation of findings from the initial adjunctive trials. A key limitation is that dedicated, placebo-controlled RCTs designed specifically for monotherapy are lacking.

---

Evidence Gaps and Research Uncertainty

Follow-up durations were limited in the highest-quality controlled trials. The observation of sustained use over many years relies heavily on open-label studies, which means the control and rigor of blinding found in RCTs is absent. Comparative evidence is lacking in many areas, and data for certain groups remain insufficient. It is important to remember that findings describe group patterns, not personal outcomes.

Key Studies & References

1. Fycompa (perampanel): DailyMed Drug Information: Composition and Dosage Forms

Common questions about Fycompa (FAQ)

---

Q: Does Fycompa have a Black Box Warning, and what does it cover?

A: According to official product information, Fycompa carries a Boxed Warning regarding the risk of serious psychiatric and behavioral changes. These can include feelings of aggression, hostility, or anger, as well as the potential for homicidal ideation and threats. Official information emphasizes the importance of closely monitoring for any unusual changes in mood or behavior during treatment.

---

Q: What is Fycompa's safety rating regarding driving or operating machinery?

A: Regulatory documents strongly advise against driving or operating heavy machinery until a patient is certain how Fycompa affects them. This guidance is in place because common side effects such as dizziness, sleepiness, and unsteadiness could impair coordination. Patients are instructed to consult their healthcare provider for specific guidance before resuming these activities.

---

Q: What are the signs of a serious allergic reaction to Fycompa?

A: Official patient safety information describes that serious allergic reactions, including conditions like DRESS or Stevens-Johnson Syndrome (SJS), can involve the skin and internal organs. Signs can include a skin rash, hives, or fever, along with swollen glands or swelling of the face, lips, tongue, or throat. Additionally, yellowing of the skin or eyes (jaundice) may be observed.

---

Q: Does Fycompa come in different strengths?

A: Yes, Fycompa is available in multiple strengths in both tablet and suspension form. The film-coated tablets are available in strengths ranging from 2 mg to 12 mg. For patients who may have difficulty swallowing tablets, an oral suspension is also available at a concentration of 0.5 mg/mL.

---

Q: How is Fycompa processed and eliminated from the body?

A: According to regulatory documents, the body processes Fycompa primarily through metabolism by certain liver enzymes, mainly the CYP3A4 system. After this process, the drug is eliminated over time. Approximately 70% of the drug is excreted in the feces, and the remaining 30% is eliminated in the urine.

---

Q: What is the half-life of Fycompa?

A: Based on clinical pharmacology data, Fycompa has a relatively long terminal half-life in the human body. The half-life, which describes the time it takes for the concentration of the drug in the body to decrease by half, is approximately 105 hours. This long duration is a characteristic of the medicine's overall behavior in the body.

---

Q: Does Fycompa cause physical dependence?

A: Yes, official product labeling states that Fycompa is classified as a Schedule III Controlled Substance. This classification is due to the potential for abuse and the development of physical dependence. Due to this risk, the drug requires a gradual reduction in dosage when discontinued.

---

Q: Is Fycompa available as a generic drug (perampanel)?

A: Yes, the active ingredient in Fycompa, perampanel, is available in generic form. The U.S. Food and Drug Administration (FDA) has officially approved generic versions of both the tablets and the oral suspension. Availability, however, is subject to the specific marketing and patent status of the drug.

---

Q: How often is blood monitoring needed while taking Fycompa?

A: Routine laboratory tests, such as monitoring drug levels or blood cell counts, are not generally required for this medication. However, because of the risk of serious psychiatric effects, official warnings state that monitoring for psychiatric and behavioral changes is important, especially when starting treatment or increasing the dose.

---

Q: Is Fycompa prescribed for any conditions other than epilepsy?

A: No. The official indications are restricted to the treatment of partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients who meet specific age criteria. This means the drug is authorized only for these specific forms of epilepsy.

---

Q: What is the recommended procedure if a dose of Fycompa is forgotten?

A: The official instructions indicate that if one dose is missed, the patient should skip that dose and take the next dose at the regular time; patients are instructed not to take two doses to make up for the missed one. If more than one dose is missed, consulting the prescribing healthcare provider for guidance is advised.

---

Q: Are there any known long-term side effects of taking Fycompa?

A: Fycompa is considered a treatment intended for long-term management of seizure disorders. While controlled clinical trials used for approval were limited in duration, information on its safety and use over many years comes from ongoing, less-controlled open-label extension studies. These official documents describe its long-term safety profile based on that evidence.

---

Q: Why is Fycompa associated with serious psychiatric or behavioral side effects?

A: The drug works by interacting with the AMPA receptor, which helps control neuronal excitation mediated by the neurotransmitter glutamate in the brain. Because Fycompa acts directly on the central nervous system (CNS) to dampen this activity, it has the potential to produce CNS-related adverse effects, including the serious behavioral changes described in official warnings.

---

Q: What does the latest research indicate about Fycompa's use in refractory epilepsy?

A: Regulatory approval for Fycompa as an add-on therapy is supported by controlled clinical trials that focused on patients with epilepsy whose seizures were not adequately controlled by other conventional treatments. These studies demonstrated the drug's role in achieving a reduction in seizure frequency within this refractory population.

---

Q: Do side effects from Fycompa usually go away over time?

A: Official product information indicates that the most common side effects, such as dizziness, sleepiness, and fatigue, are often reported during the initial titration phase when the dose is being gradually increased. Because these effects are also generally dose-dependent, they are most notable during this starting period of treatment.

---

Q: Does Fycompa interact with herbal supplements like St. John's Wort?

A: Yes, regulatory documents advise that using Fycompa with St. John's Wort is not recommended. This herbal supplement is known to be a strong enzyme inducer, and using it alongside Fycompa may cause the level of Fycompa in the body to significantly decrease, potentially reducing its effectiveness.

---

Q: Is it safe to take common cold medicine or decongestants with Fycompa?

A: The official safety warnings advise caution when taking Fycompa with other central nervous system (CNS) depressants. Since many common cold and allergy medicines contain ingredients that also cause CNS depression, combining them with Fycompa may increase the risk of side effects such as profound dizziness, sleepiness, or unsteadiness.

---

Q: Does Fycompa lose its effectiveness over time (tolerance)?

A: Evidence from long-term open-label extension studies has examined the sustained effect of Fycompa over multiple years. The data from these studies indicate that the observed reduction in seizure frequency was maintained throughout the study period, suggesting a continued effect over time.

How to Store and Dispose of Fycompa?

The official storage conditions for Fycompa (perampanel) vary by formulation:

• Tablets: Must be stored at controlled room temperature, between 68 F and 77 F (20 C and 25 C).
• Oral Suspension: Must be stored below 86 F (30 C) and must not be frozen. The suspension must be used within 90 days after the bottle is first opened.

All forms must be kept in the original container and stored out of the reach of children. Due to its classification as a Schedule III controlled substance, Fycompa must be kept in a safe place to protect it from theft. The disposal of any unused or expired product must follow specific federal regulations for controlled substances, and patients should consult their pharmacist for proper instructions.